Ballicules.com

Rifabutin

MYCOBUTIN

What it isRNA-polymerase-inhibiting rifamycin; mycobacterial prophylaxis and treatment in people with HIV.

Why this oneMuch weaker enzyme induction than rifampin permits combinations with some antiretrovirals that rifampin disrupts.

What limits itUveitis and neutropenia require attention; interactions remain bidirectional, and body fluids turn orange.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Disseminated MAC prophylaxis (advanced HIV)adult300 mg QD300 mg QD300 mg QD

Renal Mild-moderate: no adjustment; CrCl <30: consider 50% dose reduction if toxicity suspected

Hepatic Mild: no adjustment; moderate-severe: not studied

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Use only if potential benefit justifies risk; animal fetal effects (decreased viability, skeletal variants)

Lactation Undefined

NO BOXED WARNINGS

Principal riskUveitis and neutropenia

Cost, est. cash$10–$300/month

Generic entry2014

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Rifabutin ballicule

Rifabutin ballicule: receptor binding, kinetics and half-life diagram

Open Rifabutin in the interactive console ↗